Targeting Pim-1 kinase for potential drug-development
by Nikhil Gadewal; Ashok Varma
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 5, No. 2, 2012

Abstract: Dysregulation of Pim-1 kinase has been implicated in several human cancers. Many potential inhibitors of PIM kinase have been reported, but potential bioactive compounds are still far from reach. Keeping this in mind, we have selected structurally known diverse Pim-1 kinase inhibitors to find novel small molecule drug-leads. A ligand-based pharmacophore model for Pim-1 kinase was developed using PHASE software. A four feature pharmacophoric hypothesis (AAHR) was used to develop atom-based 3D-QSAR model with the best regression coefficient of 0.9433 and Pearson-R of 0.9344. Compounds from Asinex platinum database were obtained whose pIC₅₀ values matched the 3D-QSAR model. Structural and molecular interaction studies on the training and test sets suggest that designing novel compounds hydrogen bond with Asp128 in the bioactive region of Pim-1 kinase would result in therapeutic success.

Online publication date: Fri, 05-Dec-2014

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com